Literature DB >> 6198441

Prostaglandin A inhibits the replication of vesicular stomatitis virus: effect on virus glycoprotein.

M G Santoro, B M Jaffe, M Esteban.   

Abstract

Prostaglandins of the A series were found to strongly suppress the replication of vesicular stomatitis virus (VSV) in mouse L fibroblasts. The highest non-toxic dose of PGA1, 4 micrograms/ml, decreased VSV production by 93.6%. At this dose, PGA1 did not alter DNA, RNA or protein synthesis in uninfected L cells for periods up to 24 h, whereas it further suppressed protein synthesis and slightly increased RNA synthesis in VSV-infected cells. The presence of PGA1 during virus adsorption, with no treatment after infection, reduced VSV yields by 63.6%. However, the presence of PGA1 during an early step of VSV replication was not essential for the antiviral action to occur (PGA1 treatment could be started 1 to 2 h post-infection). Apart from a slight overall inhibition of virus protein synthesis, PGA1 strongly suppressed the synthesis of the VSV glycoprotein G; moreover, it produced an alteration in the mobility of this protein in SDS-polyacrylamide gels. We propose that this slight decrease in molecular weight (about 4000) of the G protein in the presence of PGA1 could be due to an alteration in the glycosylation process.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6198441     DOI: 10.1099/0022-1317-64-12-2797

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus.

Authors:  M G Santoro; C Favalli; A Mastino; B M Jaffe; M Esteban; E Garaci
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

2.  Effects of dimethyl prostaglandin A1 on herpes simplex virus and human immunodeficiency virus replication.

Authors:  M Hughes-Fulford; M S McGrath; D Hanks; S Erickson; L Pulliam
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

3.  Inhibition of poliovirus replication by prostaglandins A and J in human cells.

Authors:  C Conti; P Mastromarino; P Tomao; A De Marco; F Pica; M G Santoro
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

4.  Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells. Evidence for a transcriptional block.

Authors:  C Rozera; A Carattoli; A De Marco; C Amici; C Giorgi; M G Santoro
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

5.  Selective inhibition of virus protein synthesis by prostaglandin A1: a translational block associated with HSP70 synthesis.

Authors:  C Amici; C Giorgi; A Rossi; M G Santoro
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

Review 6.  Heat shock proteins and virus replication: hsp70s as mediators of the antiviral effects of prostaglandins.

Authors:  M G Santoro
Journal:  Experientia       Date:  1994-11-30

7.  Transactivator protein BICP0 of bovine herpesvirus 1 (BHV-1) is blocked by prostaglandin D2 (PGD2), which points to a mechanism for PGD2-mediated inhibition of BHV-1 replication.

Authors:  Okay Saydam; Carlos Abril; Bernd Vogt; Mathias Ackermann; Martin Schwyzer
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence.

Authors:  Anna Riccio; Silvia Santopolo; Antonio Rossi; Sara Piacentini; Jean-Francois Rossignol; M Gabriella Santoro
Journal:  Cell Mol Life Sci       Date:  2022-04-07       Impact factor: 9.207

9.  Reversible restriction of vesicular stomatitis virus in permissive cells treated with inhibitors of prostaglandin biosynthesis.

Authors:  P K Mukherjee; R W Simpson
Journal:  Virology       Date:  1984-06       Impact factor: 3.616

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.